RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

RESULTS OF AN OPEN-LABEL COMPARATIVE RANDOMIZED CLINICAL TRIAL OF AXOGLATIRAN® FS (F-SINTEZ, RUSSIA) EFFICIENCY AND SAFETY IN COMPARISON WITH COPAXONE®-TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

Objective. Comparison of Axoglatiran® FS (F-Sintez,  Russia) and Copaxone®-Teva (Teva Pharmaceutical Industries Ltd.,  Israel) efficiency and safety in patients with relapsing-remitting multiple sclerosis. Materials and methods. In the study 150 patients with relapsing-remitting multiple sclerosis w...

Full description

Saved in:
Bibliographic Details
Main Authors: F. A. Khabirov, T. I. Khaibullin, E. V. Granatov, N. N. Babicheva, L. A. Aver’yanova, S. R. Shakirzyanova
Format: Article
Language:Russian
Published: ABV-press 2017-01-01
Series:Нервно-мышечные болезни
Subjects:
axoglatiran® fs
copaxone®-teva
multiple sclerosis
efficiency
tolerability
safety
Online Access:https://nmb.abvpress.ru/jour/article/view/177
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://nmb.abvpress.ru/jour/article/view/177

Similar Items